SCHEMBL7255753

SCHEMBL7255753

CC(C)(C)c1ccc2c(c1)[nH]c1cc(O)ccc12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 9/20 0.66
LMNA P02545 2/20 0.48
TYR P14679 1/20 0.48
ALDH1A1 P00352 6/20 0.47
HPGD P15428 5/20 0.47
KDM4E B2RXH2 4/20 0.47
GAA P10253 2/20 0.47
GLA P06280 1/20 0.47
HSD17B10 Q99714 4/20 0.44
TDP1 Q9NUW8 2/20 0.44
ALOX15 P16050 1/20 0.44
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
MAPT P10636 3/20 0.42
CASP1 P29466 3/20 0.42
CASP7 P55210 3/20 0.42
CYP2D6 P10635 2/20 0.42
BRCA1 P38398 2/20 0.42
RECQL P46063 2/20 0.42
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2606005 0.88 KIF11 (0.81) KIF11ALDH1A1HPGDHSD17B10TDP1
SCHEMBL29539315 0.88 KIF11 (0.81) KIF11ALDH1A1HPGDHSD17B10TDP1
Bromide SCHEMBL30567841 0.86 KIF11 (0.78) KIF11ALDH1A1HPGDHSD17B10TDP1
SCHEMBL124178 0.82 KDM4E (0.57) LMNATYRALDH1A1HPGDKDM4E
SCHEMBL29365550 0.82 KDM4E (0.57) LMNATYRALDH1A1HPGDKDM4E
SCHEMBL7254527 0.81 KIF11 (0.66) KIF11MAPT
SCHEMBL23327761 0.81 KIF11 (0.76) KIF11
SCHEMBL30881120 0.81 KIF11 (0.76) KIF11
SCHEMBL31228901 0.81 KIF11 (0.76) KIF11
SCHEMBL29362207 0.79 KIF11 (1.00) KIF11ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030040538-A1 Novel substituted tricyclic compounds ASAHI-KASEI KABUSHIKI KAISHA (JP) 2003-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030040538-A1 Novel substituted tricyclic compounds CPT1A, CBR1, NR1H3 KIF11 4358/4885LMNA 3664/4885TYR 1798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.